Clinicaltrials.gov ID
EudraCT ID
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A placebo-controlled, single blind, randomized two part study toinvestigate the tolerability, pharmacokinetics, and brainDopamine D3 receptor occupancy of increasing repeat doses ofGSK618334 for up to 21 days in healthy volunteers.
Trial description: The proposed study will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of repeated oral doses of GSK618334 in healthy male and female volunteers.
Primary purpose:
Other
Trial design:
Single Group Assignment
Masking:
Double (Participant, Investigator)
Allocation:
Randomized
Primary outcomes:
The safety and tolerability endpoints will be: adverse events, laboratory values, cardiovascular variables (blood pressure, heart rate, ECG), temperature, respiratory rate, assessment of mood and abnormal movements, and GSK618334 blood levels.
Timeframe: First dose to follow-up
To assess blood concentrations of GSK618334 after repeated oral doses.
Timeframe: First dose to 72 hours post last dose
Secondary outcomes:
To assess the effect of food on GSK618334 blood concentrations after a single dose.
Timeframe: First dose of the single dose session to 24 hours after dosing of the repeat dose session
The dopamine type 3 receptor binding in the brain (by PET scan) of GSK618334 following the repeat dose session.
Timeframe: First dose to 24 hours after last dose
Interventions:
Enrollment:
46
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Not applicable
Medical condition
Substance Dependence
Product
GSK618334
Collaborators
Not applicable
Study date(s)
September 2009 to February 2010
Type
Interventional
Phase
1
Participation criteria
Sex
Female & Male
Age
18 - 50 years
Accepts healthy volunteers
Yes
- Healthy Males and Females between the ages of 18-50 years old
- Male and Female subjects must agree to use protocol specified contraceptive methods.
- A positive test for Hepatitis B or Hepatitis C within 3 months of screening.
- Current or chronic history of liver disease, or known liver/bile/gallbladder abnormalities.
Inclusion and exclusion criteria
Inclusion criteria:
- Healthy Males and Females between the ages of 18-50 years old
- Male and Female subjects must agree to use protocol specified contraceptive methods.
- Male subjects only in PET parts of the study.
- Capable of providing written informed consent.
Exclusion criteria:
- A positive test for Hepatitis B or Hepatitis C within 3 months of screening.
- Current or chronic history of liver disease, or known liver/bile/gallbladder abnormalities.
- Personal or family history of heart disease (such as irregular heart beats, a history of sudden unexplained death in a first degree relative, or unexplained fainting).
- Screening ECG parameters outside the protocol specified parameters.
- Pulse rate <50 or >100 bpm OR a systolic blood pressure >140 or <95 mmHg OR a diastolic blood pressure >90 or <50 mmHg at screening and/or baseline.
- Pregnant or lactating females.
- Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
- Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
- Previous inclusion in a research and/or medical protocol involving nuclear medicine, PET or radiological investigations with significant radiation burden.
- Significant suicidal risk.
Trial location(s)
Study documents
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Refer to study documents
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
2010-17-02
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Participate in clinical trial
Additional information
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Click hereResults for study 108414 can be found on the GSK Clinical Study Register.
Click hereAccess to clinical trial data by researchers
Visit website